$BCDA
BioCardia, Inc. Stock $bcda

$bcda Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000143774922007544 Filed on March 29, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$79.00K	$1.015M	$50.00K
YoY Change	58.0%	600.0%	-77.27%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit	$79.00K	$1.015M	$50.00K
YoY Change	58.0%	619.86%	-72.22%
Gross Profit Margin	100.0%	100.0%	100.0%
Selling, General & Admin	$1.425M	$5.087M	$1.220M
YoY Change	16.8%	-13.21%	-20.78%
% of Gross Profit	1803.8%	501.18%	2440.0%
Research & Development	$2.115M	$8.558M	$2.330M
YoY Change	-9.23%	-12.75%	7.37%
% of Gross Profit	2677.22%	843.15%	4660.0%
Depreciation & Amortization	$15.00K	$60.00K	$20.00K
YoY Change	-25.0%	-11.76%	-33.33%
% of Gross Profit	18.99%	5.91%	40.0%
Operating Expenses	$3.540M	$13.65M	$3.550M
YoY Change	-0.28%	-12.92%	-4.31%
Operating Profit	-$3.461M	-$12.63M	-$3.500M
YoY Change	-1.11%	-18.67%	-0.85%
Interest Expense	$1.000K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$1.000K	$7.000K	$0.00
YoY Change		-98.67%
Pretax Income	-$3.461M	-$12.62M	-$2.990M
YoY Change	15.75%	-15.85%	-14.57%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.461M	-$12.62M	-$2.990M
YoY Change	15.75%	-15.87%	-14.57%
Net Earnings / Revenue	-4381.01%	-1243.65%	-5980.0%
Basic Earnings Per Share		-$0.75
Diluted Earnings Per Share	-$202.8K	-$746.1K	-$224.8K
COMMON SHARES
Basic Shares Outstanding	16.87M	16.92M	12.43M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.87M	$12.87M	$21.41M
YoY Change	-39.88%	-39.88%	283.01%
Cash & Equivalents	$12.87M	$12.87M	$21.41M
Short-Term Investments
Other Short-Term Assets	$462.0K	$462.0K	$400.0K
YoY Change	15.5%	15.5%	-37.5%
Inventory
Prepaid Expenses
Receivables	$147.0K	$147.0K	$232.0K
Other Receivables	$0.00	$0.00	$620.0K
Total Short-Term Assets	$13.48M	$13.48M	$22.66M
YoY Change	-40.5%	-40.51%	255.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$182.0K	$2.065M	$145.0K
YoY Change	25.52%	190.85%	-19.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$172.0K	$172.0K	$54.00K
YoY Change	218.52%	244.0%	0.0%
Total Long-Term Assets	$2.237M	$2.237M	$766.0K
YoY Change	192.04%	194.34%	-41.08%
TOTAL ASSETS
Total Short-Term Assets	$13.48M	$13.48M	$22.66M
Total Long-Term Assets	$2.237M	$2.237M	$766.0K
Total Assets	$15.72M	$15.72M	$23.42M
YoY Change	-32.9%	-32.89%	205.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$507.0K	$507.0K	$746.0K
YoY Change	-32.04%	-32.4%	-18.38%
Accrued Expenses	$240.0K	$1.672M	$87.00K
YoY Change	175.86%	-20.76%	770.0%
Deferred Revenue	$847.0K		$683.0K
YoY Change	24.01%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.712M	$3.712M	$4.248M
YoY Change	-12.62%	-12.66%	6.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.631M	$1.631M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$1.631M	$1.631M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.712M	$3.712M	$4.248M
Total Long-Term Liabilities	$1.631M	$1.631M	$0.00
Total Liabilities	$5.343M	$5.343M	$4.248M
YoY Change	25.78%	25.72%	-19.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$128.7M		-$116.1M
YoY Change	10.87%		14.85%
Common Stock	$17.00K		$16.00K
YoY Change	6.25%		128.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.38M	$10.38M	$19.18M
YoY Change
Total Liabilities & Shareholders Equity	$15.72M	$15.72M	$23.42M
YoY Change	-32.9%	-32.89%	205.08%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$3.461M	-$12.62M	-$2.990M
YoY Change	15.75%	-15.87%	-14.57%
Depreciation, Depletion And Amortization	$15.00K	$60.00K	$20.00K
YoY Change	-25.0%	-11.76%	-33.33%
Cash From Operating Activities	-$2.975M	-$10.37M	-$3.420M
YoY Change	-13.01%	-16.11%	4.91%
INVESTING ACTIVITIES
Capital Expenditures	-$41.00K	$116.0K	$0.00
YoY Change		262.5%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$41.00K	-$116.0K	$0.00
YoY Change		262.5%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$2.001M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$1.947M	17.43M
YoY Change	-100.0%	-93.1%	-25000.0%
NET CHANGE
Cash From Operating Activities	-2.975M	-$10.37M	-3.420M
Cash From Investing Activities	-41.00K	-$116.0K	0.000
Cash From Financing Activities	0.000	$1.947M	17.43M
Net Change In Cash	-3.016M	-$8.535M	14.01M
YoY Change	-121.53%	-153.94%	-519.46%
FREE CASH FLOW
Cash From Operating Activities	-$2.975M	-$10.37M	-$3.420M
Capital Expenditures	-$41.00K	$116.0K	$0.00
Free Cash Flow	-$2.934M	-$10.48M	-$3.420M
YoY Change	-14.21%	-15.39%	5.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	22000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	16000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16871265
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16871265
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16297381
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16297381
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	59000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12Y
CY2021	bcda	Standard Product Warranty Term StandardProductWarrantyTerm	P2Y
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	0	USD
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	0	USD
CY2020Q1	bcda	Sharebased Compensation Arrangement By Sharebased Payment Award Remaining Weighted Average Award Vesting Period SharebasedCompensationArrangementBySharebasedPaymentAwardRemainingWeightedAverageAwardVestingPeriod	P3Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12872000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21407000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	147000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	232000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	462000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	401000	USD
CY2021Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	0	USD
CY2020Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	618000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	13481000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	22658000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	182000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1883000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	567000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000	USD
CY2021Q4	us-gaap	Assets Assets	15718000	USD
CY2020Q4	us-gaap	Assets Assets	23424000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	507000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8558000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9809000	USD
CY2020	us-gaap	Interest Expense InterestExpense	3000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	525000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12623000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15004000	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.75
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.48
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	746000	USD
CY2021Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2121000	USD
CY2020Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2205000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	847000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	683000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	237000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	614000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3712000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4248000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1631000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	5343000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	4248000	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139055000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135234000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128697000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116074000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10375000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19176000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15718000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23424000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1015000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	145000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5087000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5861000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	13645000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	15674000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-12630000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-15529000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	21000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	509000	USD
CY2021	us-gaap	Interest Expense InterestExpense	-0	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16917664
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10118682
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2370000	USD
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	148000	USD
CY2020	bcda	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2952000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15004000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19176000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1942000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1661000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12623000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10375000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12623000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15004000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	60000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	68000	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	3000	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-0	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	509000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1661000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2952000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-19000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-85000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	85000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	179000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-241000	USD
CY2021	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-618000	USD
CY2020	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	618000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-239000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-168000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	130000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	797000	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	164000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8000	USD
CY2021	bcda	Increase Decrease In Current Operating Lease Liability IncreaseDecreaseInCurrentOperatingLeaseLiability	-618000	USD
CY2020	bcda	Increase Decrease In Current Operating Lease Liability IncreaseDecreaseInCurrentOperatingLeaseLiability	86000	USD
CY2021	bcda	Increase Decrease In Non Current Operating Lease Liability IncreaseDecreaseInNonCurrentOperatingLeaseLiability	-24000	USD
CY2020	bcda	Increase Decrease In Non Current Operating Lease Liability IncreaseDecreaseInNonCurrentOperatingLeaseLiability	-614000	USD
CY2021	bcda	Increase Decrease In Rightofuse Assets IncreaseDecreaseInRightofuseAssets	-580000	USD
CY2020	bcda	Increase Decrease In Rightofuse Assets IncreaseDecreaseInRightofuseAssets	-498000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10366000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12357000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	116000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-116000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2001000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	59000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2635000	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	506000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	-0	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	160000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1947000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28211000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8535000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15822000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21407000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5585000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12872000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21407000	USD
CY2021	bcda	Restricted Stock Issued To Settle Management Bonus Obligations RestrictedStockIssuedToSettleManagementBonusObligations	393000	USD
CY2020	bcda	Restricted Stock Issued To Settle Management Bonus Obligations RestrictedStockIssuedToSettleManagementBonusObligations	391000	USD
CY2021	bcda	Restricted Stock Issued To Settle Board Compensation Obligations RestrictedStockIssuedToSettleBoardCompensationObligations	0	USD
CY2020	bcda	Restricted Stock Issued To Settle Board Compensation Obligations RestrictedStockIssuedToSettleBoardCompensationObligations	613000	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	148000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1896000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128700000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12900000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(c)</i></b></p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, clinical accruals and assumptions used for revenue recognition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(e)</i></b></p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at reputable U.S. financial institutions, which at times, exceed federally insured limits of <em style="font: inherit;">$250,000</em> per customer. On <em style="font: inherit;"> December 31, 2021, </em>the Company’s cash was held by <em style="font: inherit;">one</em> financial institution and the amount on deposit was in excess of FDIC insurance limits. The Company has <em style="font: inherit;">not</em> recognized any losses from credit risks on such accounts since inception. The Company believes it is <em style="font: inherit;">not</em> exposed to significant credit risk on cash and cash equivalents.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	22000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	16000	USD
CY2021	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(i)</i></b></p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Long-lived Assets</i></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;"><i>Impairment assessment of long-lived assets</i> - The carrying value of long-lived assets, including property and equipment and operating lease right-of-use assets, is reviewed for impairment whenever events or changes in circumstances indicate that the asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there have been no such impairment losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	847000	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	683000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	537000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	719000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1170000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1025000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	182000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145000	USD
CY2021	us-gaap	Depreciation Depreciation	60000	USD
CY2020	us-gaap	Depreciation Depreciation	68000	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	623000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	601000	USD
CY2021	bcda	Operating Lease Variable Lease Expense OperatingLeaseVariableLeaseExpense	322000	USD
CY2020	bcda	Operating Lease Variable Lease Expense OperatingLeaseVariableLeaseExpense	395000	USD
CY2021	us-gaap	Lease Cost LeaseCost	945000	USD
CY2020	us-gaap	Lease Cost LeaseCost	996000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1074	pure
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1205	pure
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	686000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	630000	USD
CY2021	bcda	Operating Lease Interest Expense OperatingLeaseInterestExpense	43000	USD
CY2020	bcda	Operating Lease Interest Expense OperatingLeaseInterestExpense	103000	USD
CY2021	bcda	Operating Lease Rent Expense Cash Payment Total OperatingLeaseRentExpenseCashPaymentTotal	729000	USD
CY2020	bcda	Operating Lease Rent Expense Cash Payment Total OperatingLeaseRentExpenseCashPaymentTotal	733000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	424000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	471000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	485000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	499000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	514000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	43000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2436000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	568000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1868000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28440000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2700000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3300000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87000	USD
CY2021Q4	bcda	Accrued Salaries And Employee Benefits Current AccruedSalariesAndEmployeeBenefitsCurrent	861000	USD
CY2020Q4	bcda	Accrued Salaries And Employee Benefits Current AccruedSalariesAndEmployeeBenefitsCurrent	961000	USD
CY2021Q4	bcda	Accured Clinical Trial Costs AccuredClinicalTrialCosts	334000	USD
CY2020Q4	bcda	Accured Clinical Trial Costs AccuredClinicalTrialCosts	452000	USD
CY2021Q4	bcda	Grant Liability Current GrantLiabilityCurrent	590000	USD
CY2020Q4	bcda	Grant Liability Current GrantLiabilityCurrent	615000	USD
CY2021Q4	bcda	Customer Deposit Liabilities Current CustomerDepositLiabilitiesCurrent	96000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240000	USD
CY2020Q4	bcda	Customer Deposit Liabilities Current CustomerDepositLiabilitiesCurrent	90000	USD
CY2021Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2121000	USD
CY2020Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2205000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2424724
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.36
CY2021	bcda	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	0
CY2021	bcda	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	0
CY2021	bcda	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
CY2021	bcda	Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2424724
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.36
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1661000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2952000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.32
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	515036
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	569000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	412000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	157000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1114306
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.89
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	177100	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	772435
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.56
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1580
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	235350
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	125
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.32
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1649686
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	762867
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.62
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1649686
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2021Q4	us-gaap	Share Price SharePrice	1.94
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.10
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.73
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12623000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15004000	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16917664
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10118682
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.75
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.48
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	24000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	90000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	595000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	276000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	264000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	649000	USD
CY2021	bcda	Effective Income Tax Rate Reconciliation Debt Forgiveness Amount EffectiveIncomeTaxRateReconciliationDebtForgivenessAmount	-0	USD
CY2020	bcda	Effective Income Tax Rate Reconciliation Debt Forgiveness Amount EffectiveIncomeTaxRateReconciliationDebtForgivenessAmount	107000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2664000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3332000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	686000	USD
CY2021Q4	bcda	Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent	30277000	USD
CY2020Q4	bcda	Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent	26931000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4079878
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3547230
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2651000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3151000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-449000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	279000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	191000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	225000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	15000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	335000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	173000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31104000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28440000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31104000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	30000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1235000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1046000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	158000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	189000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	25000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	-0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1368000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1235000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	991000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	895000	USD
CY2021	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">14</em>)</b></p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Contingencies and Contingencies</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><i>Contingencies</i> - The Company <em style="font: inherit;"> may </em>be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is <em style="font: inherit;">not</em> aware of any current legal or administrative proceedings that are likely to have an adverse effect on the Company’s business, financial position, results of operations, or cash flows. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.75	pure
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	26000	USD

Files In Submission

Name	View Source	Status
0001437749-22-007544-index-headers.html	Edgar Link	pending
0001437749-22-007544-index.html	Edgar Link	pending
0001437749-22-007544.txt	Edgar Link	pending
0001437749-22-007544-xbrl.zip	Edgar Link	pending
b01.jpg	Edgar Link	pending
b02.jpg	Edgar Link	pending
b03.jpg	Edgar Link	pending
b04.jpg	Edgar Link	pending
bcda-20211231.xsd	Edgar Link	pending
bcda-20211231_cal.xml	Edgar Link	unprocessable
bcda-20211231_def.xml	Edgar Link	unprocessable
bcda-20211231_lab.xml	Edgar Link	unprocessable
bcda-20211231_pre.xml	Edgar Link	unprocessable
bcda20211231_10k.htm	Edgar Link	pending
bcda20211231_10k_htm.xml	Edgar Link	completed
ex_340237.htm	Edgar Link	pending
ex_340237img005.jpg	Edgar Link	pending
ex_350099.htm	Edgar Link	pending
ex_350288.htm	Edgar Link	pending
ex_350289.htm	Edgar Link	pending
ex_350290.htm	Edgar Link	pending
ex_350291.htm	Edgar Link	pending
ex_350292.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img01.jpg	Edgar Link	pending
img02.jpg	Edgar Link	pending
img03.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCDA
BioCardia, Inc. Stock $bcda

2021 Q4 Form 10-K Financial Statement

#000143774922007544 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA BioCardia, Inc. Stock $bcda

2021 Q4 Form 10-K Financial Statement

#000143774922007544 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA
BioCardia, Inc. Stock $bcda